 |
|
Effectiveness of Oseltamivir in Preventing Influenza in Household Contacts
A Randomized Controlled Trial
Robert Welliver, MD;
Arnold S. Monto, MD;
Otmar Carewicz, MD;
Edwig Schatteman, MD;
Michael Hassman, DO;
James Hedrick, MD;
Helen C. Jackson, PhD;
Les Huson, PhD;
Penelope Ward, MD;
John S. Oxford, PhD;
for the Oseltamivir Post Exposure Prophylaxis Investigator Group
JAMA. 2001;285:748-754.
Context Influenza virus is easily spread among the household contacts of an infected person, and prevention of influenza in household contacts can control spread of influenza in the community.
Objective To investigate the efficacy of oseltamivir in preventing spread of influenza to household contacts of influenza-infected index cases (ICs).
Design and Setting Randomized, double-blind, placebo-controlled study conducted at 76 centers in North America and Europe during the winter of 1998-1999.
Participants Three hundred seventy-seven ICs, 163 (43%) of whom had laboratory-confirmed influenza infection, and 955 household contacts (aged  12 years) of all ICs (415 contacts of influenza-positive ICs).
Interventions Household contacts were randomly assigned by household cluster to take 75 mg of oseltamivir (n = 493) or placebo (n = 462) once daily for 7 days within 48 hours of symptom onset in the IC. The ICs did not receive antiviral treatment.
Main Outcome Measure Clinical influenza in contacts of influenza-positive ICs, confirmed in a laboratory by detection of virus shedding in nose and throat swabs or a 4-fold or greater increase in influenza-specific serum antibody titer between baseline and convalescent serum samples.
Results In contacts of an influenza-positive IC, the overall protective efficacy of oseltamivir against clinical influenza was 89% for individuals (95% confidence interval [CI], 67%-97%; P<.001) and 84% for households (95% CI, 49%-95%; P<.001). In contacts of all ICs, oseltamivir also significantly reduced incidence of clinical influenza, with 89% protective efficacy (95% CI, 71%-96%; P<.001). Viral shedding was inhibited in contacts taking oseltamivir, with 84% protective efficacy (95% CI, 57%-95%; P<.001). All virus isolates from oseltamivir recipients retained sensitivity to the active metabolite. Oseltamivir was well tolerated; gastrointestinal tract effects were reported with similar frequency in oseltamivir (9.3%) and placebo (7.2%) recipients.
Conclusion In our sample, postexposure prophylaxis with oseltamivir, 75 mg once daily for 7 days, protected close contacts of influenza-infected persons against influenza illness, prevented outbreaks within households, and was well tolerated.
Author Affiliations: Children's Hospital, Buffalo, NY (Dr Welliver); University of Michigan School of Public Health, Ann Arbor (Dr Monto); Comprehensive Clinical Research, Berlin, NJ (Dr Hassman); Kentucky Pediatric and Adult Research, Bardstown, Ky (Dr Hedrick); Roche Global Development, Welwyn, England (Drs Jackson, Huson, and Ward); and St Bartholomew's and Royal London Hospital School of Medicine and Dentistry, and Retroscreen Virology Ltd, London, England (Dr Oxford). Dr Carewicz is in private practice in Heidelberg, Germany, and Dr Schatteman is in private practice in Drogen, Ghent, Belgium.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A Primer on Strategies for Prevention and Control of Seasonal and Pandemic Influenza
Santibanez et al.
AJPH 2009;99:S216-S224.
ABSTRACT
| FULL TEXT
Estimating antiviral effectiveness against pandemic influenza using household data
Glass and Becker
J R Soc Interface 2009;6:695-703.
ABSTRACT
| FULL TEXT
Who should receive Tamiflu for swine flu?
Ellis and McEwen
BMJ 2009;339:b2698-b2698.
FULL TEXT
A Bayesian model for evaluating influenza antiviral efficacy in household studies with asymptomatic infections
Yang et al.
Biostatistics 2009;10:390-403.
ABSTRACT
| FULL TEXT
Similarity in Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Japanese and Caucasian Subjects
Schentag et al.
J Clin Pharmacol 2007;47:689-696.
ABSTRACT
| FULL TEXT
Antiviral Therapy and Prophylaxis for Influenza in Children
Committee on Infectious Diseases
Pediatrics 2007;119:852-860.
ABSTRACT
| FULL TEXT
Avian influenza: A review
Thomas and Noppenberger
Am J Health Syst Pharm 2007;64:149-165.
ABSTRACT
| FULL TEXT
Antiviral Effects on Influenza Viral Transmission and Pathogenicity: Observations from Household-based Trials
Halloran et al.
Am J Epidemiol 2007;165:212-221.
ABSTRACT
| FULL TEXT
The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis
Robson et al.
Nephrol Dial Transplant 2006;21:2556-2562.
ABSTRACT
| FULL TEXT
Management of Influenza Symptoms in Healthy Children: Cost-effectiveness of Rapid Testing and Antiviral Therapy
Rothberg et al.
Arch Pediatr Adolesc Med 2005;159:1055-1062.
ABSTRACT
| FULL TEXT
Neuraminidase inhibitors for influenza.
Moscona
NEJM 2005;353:1363-1373.
FULL TEXT
Avian influenza A (H5N1) infection in humans.
Beigel
NEJM 2005;353:1374-1385.
FULL TEXT
Containing Pandemic Influenza at the Source
Longini et al.
Science 2005;309:1083-1087.
ABSTRACT
| FULL TEXT
Prevention of influenza in the general population
Langley and Faughnan
CMAJ 2004;171:1213-1222.
ABSTRACT
| FULL TEXT
Tackling the next influenza pandemic
Balicer et al.
BMJ 2004;328:1391-1392.
FULL TEXT
Containing Pandemic Influenza with Antiviral Agents
Longini et al.
Am J Epidemiol 2004;159:623-633.
ABSTRACT
| FULL TEXT
A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community
Oxford et al.
J Antimicrob Chemother 2004;53:133-136.
ABSTRACT
| FULL TEXT
Assessing the Validity of Published Randomized Controlled Trials in Podiatric Medical Journals
Turlik et al.
J. Am. Podiatr. Med. Assoc. 2003;93:392-398.
ABSTRACT
| FULL TEXT
How Contagious Are Common Respiratory Tract Infections?
Musher
NEJM 2003;348:1256-1266.
FULL TEXT
The treatment of influenza with antiviral drugs
Stiver
CMAJ 2003;168:49-57.
ABSTRACT
| FULL TEXT
Update in Infectious Diseases
Lorber
ANN INTERN MED 2002;137:974-980.
FULL TEXT
{blacktriangledown}Oseltamivir for influenza
DTB 2002;40:89-91.
ABSTRACT
| FULL TEXT
Technical Report: Reduction of the Influenza Burden in Children
Rennels et al.
Pediatrics 2002;110:e80-e80.
ABSTRACT
| FULL TEXT
Reduction of the Influenza Burden in Children
Committee on Infectious Diseases
Pediatrics 2002;110:1246-1252.
ABSTRACT
| FULL TEXT
Influenza Burden of Illness: Estimates From a National Prospective Survey of Household Contacts in France
Carrat et al.
Arch Intern Med 2002;162:1842-1848.
ABSTRACT
| FULL TEXT
Influenza Vaccination for Healthy Young Adults
Ahmed et al.
NEJM 2001;345:1543-1547.
FULL TEXT
Oseltamivir reduced new cases of influenza in household contacts of people with clinical or confirmed influenza
Haley
Evid. Based Med. 2001;6:141-141.
FULL TEXT
|
